Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
The final obstacle to the routine use of Sanofi and AstraZeneca's Beyfortus to prevent respiratory syncytial virus (RSV) in the US has fallen after it was backed by Centre
GSK has filed a lawsuit against Pfizer in a US court alleging infringement of patents that it holds on vaccines against respiratory syncytial virus (RSV).<
A potentially game-changing new vaccine for tuberculosis is set for a major clinical trials programme, thanks to $550 million in funding from philanthropic organisations t
The FDA has given a fast-track designation to a gonorrhoea vaccine in development at GSK that could help turn the tide of the sexually-transmitted infection, which is on t
With an FDA decision in its marketing application for chikungunya vaccine VLA1553 just a couple of months away, Valneva has published data reinforcing the clinical evidenc
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho